Under the conditions of this study, 2,3-dimercaptosuccinic acid was not effective in producing any clinical or biochemical benefit or any histopathological improvement of skin lesions in patients with chronic arsenicosis.

No abstract

No abstract

<b><i>Introduction:</i></b> Individualized homeopathy (IH) in atopic dermatitis (AD) remained under-researched. <b><i>Objective:</i></b> We aimed at evaluating efficacy of IH in AD. <b><i>Methods:</i></b> A double-blind, randomized, placebo-controlled, short-term, preliminary trial was conducted in an Indian homeopathy hospital. Patients were randomized to either IH (<i>n</i> = 30) or identical-looking placebo (<i>n</i> = 30) using computerized randomization and allocation. Outcomes were patient-oriented scoring of AD (PO-SCORAD; primary end point), Dermatological Life Quality Index (DLQI) score, and AD burden score for adults (ADBSA; secondary end points), measured monthly for 3 months. An intention-to-treat sample was analyzed after adjusting baseline differences. <b><i>Results:</i></b> On PO-SCORAD, improvement was higher in IH against placebo, but nonsignificant statistically (<i>p</i>_{month 1} = 0.433, <i>p</i>_{month 2} = 0.442, <i>p</i>_{month 3} = 0.229). Secondary outcomes were also nonsignificant – both DLQI and ADBSA (<i>p</i> &#x3e; 0.05). Four adverse events (diarrhea, injury, common cold) were recorded. <b><i>Conclusions:</i></b> There was a small, but nonsignificant direction of effect towards homeopathy, which renders the trial inconclusive. A properly powered robust trial is indicated.